⌘K
Loading ticker…
As of 2026-08-24, Kymera Therapeutics, Inc. Common Stock (KYMR) has a 3-month relative strength percentile of 94 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 75. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.1%, relative volume 0.70×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
KYMR is in a stage 2 uptrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 10.6% / 40.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
KYMR is held by 32 ETFs as of May 2026. Top owner: SCHA at 0.11% weight, $24M notional. Top 3 carry $60M.
Held by 79 ETFs · $873M across latest filings · largest weight 4.23% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.11% | $24M | −0.02 pp |
| VTWO | 0.14% | $24M | −0.03 pp |
| VHTVanguard Health Care ETF | 0.06% | $12M | — |
| SBIO | 4.23% | $7M | −0.42 pp |
| VTWG | 0.26% | $4M | −0.07 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.01% |
| $3M |
| — |
| VFMO | 0.14% | $3M | +0.01 pp |
| ONEQ | 0.01% | $2M | — |
| ESML | 0.06% | $1M | −0.01 pp |
| DWAS | 0.33% | $1M | −0.07 pp |
Showing 10 of 32 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KYMR Jan avg: 17.59% median: 13.58% win: 50% σ: 26.53% n: 4 2022-04-12 → 2026-07-31 | KYMR Feb avg: 4.77% median: 4.81% win: 50% σ: 26.92% n: 4 2022-04-12 → 2026-07-31 | KYMR Mar avg: -8.24% median: -7.34% win: 0% σ: 3.31% n: 4 2022-04-12 → 2026-07-31 | KYMR Apr avg: 0.31% median: -2.67% win: 40% σ: 16.39% n: 5 2022-04-12 → 2026-07-31 | KYMR May avg: -15.74% median: -6.66% win: 20% σ: 22.23% n: 5 2022-04-12 → 2026-07-31 | KYMR Jun avg: 19.42% median: 37.98% win: 60% σ: 31.56% n: 5 2022-04-12 → 2026-07-31 | KYMR Jul avg: 10.45% median: 0.25% win: 60% σ: 26.05% n: 5 2022-04-12 → 2026-07-31 | KYMR Aug avg: 3.59% median: -0.58% win: 50% σ: 17.98% n: 4 2022-04-12 → 2026-07-31 (current) | KYMR Sep avg: -3.72% median: -12.56% win: 25% σ: 29.51% n: 4 2022-04-12 → 2026-07-31 | KYMR Oct avg: 7.53% median: 3.40% win: 50% σ: 23.61% n: 4 2022-04-12 → 2026-07-31 | KYMR Nov avg: 21.16% median: 5.62% win: 75% σ: 38.27% n: 4 2022-04-12 → 2026-07-31 | KYMR Dec avg: 2.32% median: 0.38% win: 50% σ: 19.12% n: 4 2022-04-12 → 2026-07-31 |